JP2020518582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518582A5 JP2020518582A5 JP2019559304A JP2019559304A JP2020518582A5 JP 2020518582 A5 JP2020518582 A5 JP 2020518582A5 JP 2019559304 A JP2019559304 A JP 2019559304A JP 2019559304 A JP2019559304 A JP 2019559304A JP 2020518582 A5 JP2020518582 A5 JP 2020518582A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline
- hydrate
- pharmaceutical composition
- succinate
- oxalate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762492571P | 2017-05-01 | 2017-05-01 | |
| US62/492,571 | 2017-05-01 | ||
| PCT/US2018/030144 WO2018204236A1 (en) | 2017-05-01 | 2018-04-30 | Crystalline forms of a jak inhibitor compound |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518582A JP2020518582A (ja) | 2020-06-25 |
| JP2020518582A5 true JP2020518582A5 (cg-RX-API-DMAC7.html) | 2021-05-06 |
| JP7096268B2 JP7096268B2 (ja) | 2022-07-05 |
Family
ID=62165729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559304A Expired - Fee Related JP7096268B2 (ja) | 2017-05-01 | 2018-04-30 | Jak阻害剤化合物の結晶形態 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10251874B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3619208B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7096268B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200003121A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110603255B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018261591B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059790A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX389014B (cg-RX-API-DMAC7.html) |
| MY (1) | MY200348A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12019502425A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909376TA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI808083B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018204236A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI710560B (zh) | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ip有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
| TWI754019B (zh) | 2017-03-09 | 2022-02-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 含有4員雜環醯胺之jak抑制劑 |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| AU2018261588A1 (en) | 2017-05-01 | 2019-10-31 | Theravance Biopharma R&D Ip, Llc | Methods of treatment using a JAK inhibitor compound |
| BR112021004063A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | amidas heterocíclicas com 5 a 7 membros como inibidores de jak |
| BR112021004087A2 (pt) | 2018-09-04 | 2021-05-25 | Theravance Biopharma R&D Ip, Llc | processo para preparar inibidores de jak e seus intermediários |
| DK3837258T3 (da) | 2018-09-04 | 2024-07-22 | Theravance Biopharma R&D Ip Llc | Dimethyl amino azetidine amides as jak inhibitors |
| EP3853229A1 (en) | 2018-10-29 | 2021-07-28 | Theravance Biopharma R&D IP, LLC | 2-azabicyclo hexane compound as jak inhibitor |
| KR20220149585A (ko) | 2020-03-02 | 2022-11-08 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 억제제 화합물의 결정성 수화물 |
| CA3212635A1 (en) * | 2021-03-26 | 2022-09-29 | Theravance Biopharma R&D Ip, Llc | Crystalline form of a dihydrochloride salt of a jak inhibitor compound |
| TW202317550A (zh) | 2021-06-25 | 2023-05-01 | 美商施萬生物製藥研發 Ip有限責任公司 | 作為jak抑制劑之咪唑吲唑化合物 |
| CN118401508A (zh) * | 2021-12-17 | 2024-07-26 | 株式会社大熊制药 | (2R,3S)-2-(3-(4,5-二氯-1H-苯并[d]咪唑-1-基)丙基)哌啶-3-醇的新酸加成盐及晶形 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7872014B2 (en) | 2003-07-23 | 2011-01-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ttk阻害作用を有するインダゾール誘導体 |
| CA2756989A1 (en) | 2009-04-03 | 2010-10-07 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| SMT201700581T1 (it) | 2009-12-21 | 2018-01-11 | Samumed Llc | 1h-pirazolo[3,4-b]piridine e loro usi terapeutici |
| US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| LT3077395T (lt) | 2013-12-05 | 2018-02-12 | Pfizer Inc. | Pirolo[2,3-d]pirimidinilo, pirolo[2,3-b]pirazinilo ir pirolo[2,3-d]piridinilo akrilamidai |
| PE20161475A1 (es) | 2014-05-14 | 2017-01-08 | Pfizer | Pirazolopiridinas y pirazolopirimidinas |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
| DK3712152T3 (da) | 2015-11-03 | 2021-03-22 | Topivert Pharma Ltd | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer |
| EP3831830A1 (en) | 2015-11-03 | 2021-06-09 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| TWI710560B (zh) * | 2015-11-03 | 2020-11-21 | 美商施萬生物製藥研發Ip有限責任公司 | 用於治療呼吸疾病之jak激酶抑制劑化合物 |
-
2018
- 2018-04-30 EP EP18724753.1A patent/EP3619208B1/en active Active
- 2018-04-30 AU AU2018261591A patent/AU2018261591B2/en not_active Ceased
- 2018-04-30 CA CA3059790A patent/CA3059790A1/en active Pending
- 2018-04-30 US US15/966,452 patent/US10251874B2/en active Active
- 2018-04-30 MX MX2019012945A patent/MX389014B/es unknown
- 2018-04-30 WO PCT/US2018/030144 patent/WO2018204236A1/en not_active Ceased
- 2018-04-30 KR KR1020197035428A patent/KR20200003121A/ko not_active Abandoned
- 2018-04-30 CN CN201880029410.5A patent/CN110603255B/zh not_active Expired - Fee Related
- 2018-04-30 SG SG11201909376T patent/SG11201909376TA/en unknown
- 2018-04-30 TW TW107114723A patent/TWI808083B/zh not_active IP Right Cessation
- 2018-04-30 JP JP2019559304A patent/JP7096268B2/ja not_active Expired - Fee Related
- 2018-04-30 MY MYPI2019005859A patent/MY200348A/en unknown
-
2019
- 2019-10-25 PH PH12019502425A patent/PH12019502425A1/en unknown